[State Food and Drug Administration: Establishing a market exclusivity period system for children’s drugs, rare disease drugs and other fields to make corporate R&D investments more secure] On September 20, Yang Sheng, deputy director of the State Food and Drug Administration, said at a press conference of the State Council Information Office that the implementation of the drug experimental data protection system will be promoted and a market exclusivity period system for children’s drugs, rare disease drugs and other fields will be established to make corporate R&D investments more secure. Improve the communication and exchange mechanism for early R&D, and strengthen pre-guidance for innovative drugs with new targets and new mechanisms, so that enterprises can avoid detours in R&D. Expand medical devices, transform clinical innovation results into Spring Rain Action, and formulate clinical trial and review guiding principles in cutting-edge fields such as brain-computer interfaces to pave the way for future industries.